Lead Product(s) : Tividenofusp Alpha,Idursulfase
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The safety profile of DNL310 (Recombinant Iduronate 2-sulfatase) with up to 85 weeks of dosing remains similar to standard of care. The most frequent treatment-emergent adverse events (TEAEs) were infusion related reactions (IRRs).
Product Name : DNL310
Product Type : Protein
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : Tividenofusp Alpha,Idursulfase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
